Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
NEW YORK, March 24, 2017 -- -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Aetna Inc. (“Aetna” or the “Company”) (NYSE:AET) and certain of its officers, on behalf of shareholders who purchased Aetna securities between August 15, 2016 and January 20, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aet.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aetna and its senior executives tried to influence Aetna’s participation in the Public Exchanges for positive treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its involvement in public health insurance exchanges if the Department of Justice (“DOJ”) tried to block the merger; (3) Aetna did not withdraw from certain public health insurance exchanges for business reasons as Defendants claimed, but to follow through on its threat of leaving the marketplace once the DOJ filed suit and to improve its litigation position; (4) Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and (5) consequently, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/aet or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Aetna you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
